The Comirnaty vaccine, manufactured by Pfizer-BioNTech, has gained conditional approval to be given as a booster shot six months after the second dose, according to the Ministry of Health.
The COVID-19 vaccination booster dose for people aged 18 and above was determined during the 365th meeting with Malaysia’s Drug Control Authority (DCA), said Health Director-General Tan Sri Dr Noor Hisham Abdullah in a statement released on 8th September.
He further elaborated that after at least six months of the second dose for those aged 18 and above, the meeting gave conditional approval for a booster dose of Pfizer’s COVID-19 vaccine, Comirnaty Concentrate for Dispersion for Injection (Comirnaty), produced by Pfizer Manufacturing Belgium NV (Belgium) and BioNTech Manufacturing GmbH, Germany.
The Cominarty vaccine is the first to be approved as the booster dose in Malaysia.
Dr Noor Hisham previously stated that Malaysia had granted conditional approval to two novel vaccination variants that only require one dosage.
The vaccines are the CanSino Biologics Inc’s Convidecia Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) and Johnson & Johnson’s Janssen COVID-19 Vaccine.
Dr Noor Hisham said that the Pfizer-BioNTech Comirnaty vaccine has been licenced for use in people aged 12 and up.
